Select Language
Free Registration

HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV)

HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Avi Tag (1)

  • Conjugate

    Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
HLD-H82E4
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&KRASG12D (KLVVVGADGV) Complex Protein (Monomer, MALS verified)
Total: 1
  • 1

HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV) Background

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*0201 KRAS (KLVVVGAGGV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and KLVVVGAGGV peptide of the KRAS.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IBC-0966IBC-0966Phase 2 ClinicalSunHo (China) BioPharmaceutical Co LtdNeoplasms
Details
BI-765063OSE-172; BI-765063Phase 1 ClinicalOse ImmunotherapeuticsSolid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
AnzurstobartBMS-986351; CC-95251Phase 1 ClinicalCelgene CorpMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
ADU-1805ADU-1805Phase 1 ClinicalAduro Biotech IncSolid tumours; Neoplasms; Neoplasm Metastasis
Details
LM-101LM-101Phase 1 ClinicalLaNova Medicines LtdLeukemia; Solid tumours; Hematologic Neoplasms; Neoplasms
Details
Q-1801Q-1801; Q 1801Phase 1 ClinicalQiyu Biotechnology (Shanghai) Co LtdSolid tumours
Details
Recombinant humanized IgG4 anti-SIRPα antibody（Daiichi Sankyo）DS-1103aPhase 1 ClinicalDaiichi Sankyo Co LtdSolid tumours; Breast Neoplasms
Details
ELA-026ELA-026Phase 1 ClinicalElectra Therapeutics IncLymphohistiocytosis, Hemophagocytic
Details
BYON-4228BYON-4228Phase 1 ClinicalByondis BvSolid tumours; Lymphoma
Details
BSI-082BSI-082Phase 1 ClinicalBoaoxin Biotechnology(Nanjing) Co LtdHematologic Neoplasms; Solid tumours
Details
BR-105BR-105; BR105Phase 1 ClinicalBioRay Pharmaceutical Co LtdNeoplasms; Lymphoma, Large B-Cell, Diffuse
Details
[89Zr]Zr- BI-765063(Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim CorpSquamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
TQB-2928TQB-2928Phase 1 ClinicalHematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute
Details
BI-765080Phase 1 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Details
ES-004ES-004; ES 004-N4; ES 004-B4Phase 1 ClinicalSolid tumours; Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Relugolix/Estradiol/Norethindrone AcetateE2/NETAApprovedMyovant SciencesMYFEMBREE, RYEQOUnited StatesMenorrhagia; LeiomyomaMyovant Sciences2021-05-26Pain; Endometriosis; Leiomyoma; Menorrhagia; Uterine Neoplasms
Details
Elagolix/estradiol/norethindrone acetateApprovedAbbvie IncOriahnnUnited StatesMenorrhagiaAbbvie Inc2020-05-29Menorrhagia
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

お問い合わせ
グローバル：+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8